Literature DB >> 22224815

The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.

Pedro Weslley Rosario1, Augusto Flávio Campos Mineiro Filho, Rafela Xavier Lacerda, Davi Alves dos Santos, Maria Regina Calsolari.   

Abstract

BACKGROUND: In the presence of anti-thyroglobulin antibodies (TgAb), serum thyroglobulin (Tg) might be underestimated. Therefore, the American Thyroid Association does not recommend serum Tg after thyroid hormone withdrawal or recombinant human thyrotropin administration (stimulated Tg) and diagnostic whole-body scanning (DxWBS) in TgAb-positive patients who have serum Tg values while on thyroxine (Tg-on-T4) of <1 ng/mL. The objective of this study was to determine, in patients with differentiated thyroid cancer (DTC) who appeared to be free of disease after surgery and ablative treatment, but who had positive serum TgAb, the value of performing DxWBS and obtaining serum Tg under stimulated Tg conditions.
METHODS: There were 121 women and 15 men in the study. By selection criteria, all of them had total thyroidectomy with apparent complete tumor resection, remnant ablation with (131)I (1.1-5.5 GBq), and a post-(131)I therapy WBS that were negative for ectopic (131)I uptake. On assessment 8-12 months after (131)I ablation, their clinical exam needed to be normal, their Tg-on-T4 needed to be <1 ng/mL, and the test for TgAb needed to be positive. Stimulated Tg, neck ultrasound (US), and DxWBS were obtained from all patients. Patients with stimulated Tg >1 ng/mL without disease on US and DxWBS were evaluated by other imaging methods.
RESULTS: In 10 (7.3%) patients, stimulated Tg was >1 ng/mL. The DxWBS revealed metastases in two of these patients, and other imaging methods showed disease in three others. Stimulated Tg was <1 ng/mL in 126 patients. DxWBS revealed metastases in three of these patients, and US detected lymph node metastases in four with a negative DxWBS. Tg stimulation combined with DxWBS revealed evidence for disease in 13 (9.5%) patients. When excluding patients with a positive US, DxWBS revealed metastases in four patients, and stimulated Tg of >1 ng/mL led to detection of persistent disease by other imaging methods in two more patients.
CONCLUSIONS: Performing stimulated Tg and DxWBS at the same time seems to be useful after initial therapy in DTC patients with TgAb who do not otherwise appear to have persistent disease, even when US is negative.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22224815     DOI: 10.1089/thy.2011.0020

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  6 in total

Review 1.  Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Gary L Francis; Steven G Waguespack; Andrew J Bauer; Peter Angelos; Salvatore Benvenga; Janete M Cerutti; Catherine A Dinauer; Jill Hamilton; Ian D Hay; Markus Luster; Marguerite T Parisi; Marianna Rachmiel; Geoffrey B Thompson; Shunichi Yamashita
Journal:  Thyroid       Date:  2015-07       Impact factor: 6.568

2.  Recombinant human thyrotropin versus thyroid hormone withdrawal in differentiated thyroid carcinoma follow-up: a single center experience.

Authors:  M Sahin; B I Aydoğan; E Özkan; R Emral; S Güllü; M F Erdogan; D Çorapçıoğlu
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Jul-Sep       Impact factor: 0.877

Review 3.  Clinical review: improving the measurement of serum thyroglobulin with mass spectrometry.

Authors:  Andrew N Hoofnagle; Mara Y Roth
Journal:  J Clin Endocrinol Metab       Date:  2013-02-28       Impact factor: 5.958

Review 4.  Approach to follow-up of the patient with differentiated thyroid cancer and positive anti-thyroglobulin antibodies.

Authors:  Matthew D Ringel; Fadi Nabhan
Journal:  J Clin Endocrinol Metab       Date:  2013-08       Impact factor: 5.958

Review 5.  Personalized management of differentiated thyroid cancer in real life - practical guidance from a multidisciplinary panel of experts.

Authors:  Alfredo Campennì; Daniele Barbaro; Marco Guzzo; Francesca Capoccetti; Luca Giovanella
Journal:  Endocrine       Date:  2020-08-09       Impact factor: 3.633

6.  Influence of chronic lymphocytic thyroiditis on the risk of persistent and recurrent disease in patients with papillary thyroid carcinoma and elevated antithyroglobulin antibodies after initial therapy.

Authors:  Marina Carvalho S Côrtes; Pedro Weslley Rosario; Gabriela Franco Mourão; Maria Regina Calsolari
Journal:  Braz J Otorhinolaryngol       Date:  2017-06-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.